Real-world outcomes and treatment patterns in Colombian patients with neovascular age-related macular degeneration and diabetic macular edema
Background/Objectives: Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are the leading causes of vision loss worldwide, with significant public health implications in middle-income countries such as Colombia. Subjects and Methods: This retrospective study analyze...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-06-01
|
| Series: | The Pan-American Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/pajo.pajo_36_25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background/Objectives:
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are the leading causes of vision loss worldwide, with significant public health implications in middle-income countries such as Colombia.
Subjects and Methods:
This retrospective study analyzed the sociodemographic, clinical, and treatment characteristics of patients with nAMD and DME over a 10-year period. Antivascular endothelial growth factor therapies, the primary treatment for both conditions, were evaluated for adherence and visual acuity (VA) outcomes in a real-world clinical setting.
Results:
Mean (±standard deviation) injection rates for nAMD were 4.45 (±2.56) for aflibercept and 4.28 (±2.53) for ranibizumab, while DME rates were 4.87 (±3.10) and 4.62 (±2.99), respectively. Among eyes that completed the loading dose, the annual injection rates exceeded five, with VA gains of +2.73 letters (95% confidence interval [CI]: +2.04 to +3.41) on average. Substantial improvements were observed in patients with severe baseline impairment (≥20/200), gaining +12.5 letters (95% CI: +11.4 to +13.7).
Conclusion:
The findings emphasize the importance of adhering to recommended treatment regimens and suggest that strengthening patient education and logistical support, alongside novel therapies, could improve adherence and long-term visual outcomes for patients with these conditions in Colombia. |
|---|---|
| ISSN: | 2666-4909 |